Clinical/Translational Cancer Immunotherapy

Section edited by Dr. James L. Gulley

First-in-man clinical trials, phase II/III clinical studies, immune monitoring investigations, tumor microenvironment, host genetics and clinical outcome, combination therapies, and cell therapies.

Previous Page Page 1 of 4 Next Page
  1. Research Article

    Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment

    Brain metastases are common in patients with metastatic melanoma. With increasing numbers of melanoma patients on anti-PD-1 therapy, we sought to evaluate the safety and initial response of brain metastases tr...

    Erik S. Anderson, Michael A. Postow, Jedd D. Wolchok, Robert J. Young, Åse Ballangrud, Timothy A. Chan, Yoshiya Yamada and Kathryn Beal

    Journal for ImmunoTherapy of Cancer 2017 5:76

    Published on: 17 October 2017

  2. Research article

    High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute

    Durable remissions are observed in a fraction of metastatic melanoma patients treated with high-dose interleukin-2 (HD IL-2). Early studies reported overall (OR) and complete response (CR) rates of 16% and 8% ...

    Diwakar Davar, Fei Ding, Melissa Saul, Cindy Sander, Ahmad A. Tarhini, John M. Kirkwood and Hussein A. Tawbi

    Journal for ImmunoTherapy of Cancer 2017 5:74

    Published on: 19 September 2017

  3. Research article

    Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials

    Traditional response criteria may be insufficient to characterize full clinical benefits of anticancer immunotherapies. Consequently, endpoints such as durable response rate (DRR; a continuous response [comple...

    Howard L. Kaufman, Robert H. I. Andtbacka, Frances A. Collichio, Michael Wolf, Zhongyun Zhao, Mark Shilkrut, Igor Puzanov and Merrick Ross

    Journal for ImmunoTherapy of Cancer 2017 5:72

    Published on: 19 September 2017

  4. Research article

    Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC

    Advanced non-small cell lung cancer patients receiving TG4010, a therapeutic viral vaccine encoding human Mucin 1 and interleukin-2 in addition to standard chemotherapy, displayed longer overall survival in co...

    Caroline Tosch, Bérangère Bastien, Luc Barraud, Benoit Grellier, Virginie Nourtier, Murielle Gantzer, Jean Marc Limacher, Eric Quemeneur, Kaïdre Bendjama and Xavier Préville

    Journal for ImmunoTherapy of Cancer 2017 5:70

    Published on: 19 September 2017

  5. Research article

    Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma

    Adoptive natural killer (NK) cell transfer is being increasingly used as cancer treatment. However, clinical responses have so far been limited to patients with hematological malignancies. A potential limiting...

    Veronika Kremer, Maarten Ligtenberg, Rosa Zendehdel, Christina Seitz, Annet Duivenvoorden, Erik Wennerberg, Eugenia Colón, Ann-Helén Scherman-Plogell and Andreas Lundqvist

    Journal for ImmunoTherapy of Cancer 2017 5:73

    Published on: 19 September 2017

  6. Research article

    Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection

    Enadenotucirev (formerly ColoAd1) is a tumor-selective chimeric adenovirus with demonstrated preclinical activity. This phase 1 Mechanism of Action study assessed intravenous (IV) delivery of enadenotucirev in...

    Rocio Garcia-Carbonero, Ramon Salazar, Ignacio Duran, Ignacio Osman-Garcia, Luis Paz-Ares, Juan M. Bozada, Valentina Boni, Christine Blanc, Len Seymour, John Beadle, Simon Alvis, Brian Champion, Emiliano Calvo and Kerry Fisher

    Journal for ImmunoTherapy of Cancer 2017 5:71

    Published on: 19 September 2017

  7. Research article

    Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma

    Accumulating pre-clinical data indicate that the efficient induction of antigen-specific cytotoxic CD8+ T cells characterizing viral infections is caused by cross-priming where initially infected DCs produce a...

    Anna Laurell, Maria Lönnemark, Einar Brekkan, Anders Magnusson, Anna Tolf, Anna Carin Wallgren, Bengt Andersson, Lars Adamson, Rolf Kiessling and Alex Karlsson-Parra

    Journal for ImmunoTherapy of Cancer 2017 5:52

    Published on: 20 June 2017

  8. Research article

    Evaluation of dosing strategy for pembrolizumab for oncology indications

    Traditionally, most monoclonal antibodies (mAbs) have been dosed based on body weight because of perceived contribution of body size in pharmacokinetic variability. The same approach was used in the initial pe...

    Tomoko Freshwater, Anna Kondic, Malidi Ahamadi, Claire H. Li, Rik de Greef, Dinesh de Alwis and Julie A. Stone

    Journal for ImmunoTherapy of Cancer 2017 5:43

    Published on: 16 May 2017

  9. Research article

    Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies

    Imatinib mesylate can induce rapid tumor regression, increase tumor antigen presentation, and inhibit tumor immunosuppressive mechanisms. CTLA-4 blockade and imatinib synergize in mouse models to reduce tumor ...

    Matthew J. Reilley, Ann Bailey, Vivek Subbiah, Filip Janku, Aung Naing, Gerald Falchook, Daniel Karp, Sarina Piha-Paul, Apostolia Tsimberidou, Siqing Fu, JoAnn Lim, Stacie Bean, Allison Bass, Sandra Montez, Luis Vence, Padmanee Sharma…

    Journal for ImmunoTherapy of Cancer 2017 5:35

    Published on: 18 April 2017

  10. Meeting report

    The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary Annual Meeting

    As healthcare costs continue to rise, there has been great interest in understanding and defining the value of current therapeutic strategies for the treatment of cancer. Cancer immunotherapy has emerged as a ...

    Howard L. Kaufman, Michael B. Atkins, Adam P. Dicker, Heather S. Jim, Louis P. Garrison, Roy S. Herbst, William T. McGivney, Steven Silverstein, Jon M. Wigginton and Peter P. Yu

    Journal for ImmunoTherapy of Cancer 2017 5:38

    Published on: 18 April 2017

  11. Research article

    Nano-Pulse Stimulation is a physical modality that can trigger immunogenic tumor cell death

    We have been developing a non-thermal, drug-free tumor therapy called Nano-Pulse Stimulation (NPS) that delivers ultrashort electric pulses to tumor cells which eliminates the tumor and inhibits secondary tumo...

    Richard Nuccitelli, Amanda McDaniel, Snjezana Anand, John Cha, Zachary Mallon, Jon Casey Berridge and Darrin Uecker

    Journal for ImmunoTherapy of Cancer 2017 5:32

    Published on: 18 April 2017

  12. Research article

    A systems biology approach to investigating the influence of exercise and fitness on the composition of leukocytes in peripheral blood

    Exercise immunology has become a growing field in the past 20 years, with an emphasis on understanding how different forms of exercise affect immune function. Mechanistic studies are beginning to shed light on...

    Michael P. Gustafson, Ara Celi DiCostanzo, Courtney M. Wheatley, Chul-Ho Kim, Svetlana Bornschlegl, Dennis A. Gastineau, Bruce D. Johnson and Allan B. Dietz

    Journal for ImmunoTherapy of Cancer 2017 5:30

    Published on: 18 April 2017

  13. Research article

    Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer

    Tumor immune cell infiltrates are essential in hindering cancer progression and may complement the TNM classification. CD8+ and CD163+ cells have prognostic impact in breast cancer but their spatial heterogene...

    Sotirios P. Fortis, Michael Sofopoulos, Nectaria N. Sotiriadou, Christoforos Haritos, Christoforos K. Vaxevanis, Eleftheria A. Anastasopoulou, Nicole Janssen, Niki Arnogiannaki, Alexandros Ardavanis, Graham Pawelec, Sonia A. Perez and Constantin N. Baxevanis

    Journal for ImmunoTherapy of Cancer 2017 5:39

    Published on: 18 April 2017

    The Erratum to this article has been published in Journal for ImmunoTherapy of Cancer 2017 5:48

  14. Research article

    Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer

    T cells engineered to express chimeric antigen receptors (CARs) have established efficacy in the treatment of B-cell malignancies, but their relevance in solid tumors remains undefined. Here we report results ...

    Kristen M. Hege, Emily K. Bergsland, George A. Fisher, John J. Nemunaitis, Robert S. Warren, James G. McArthur, Andy A. Lin, Jeffrey Schlom, Carl H. June and Stephen A. Sherwin

    Journal for ImmunoTherapy of Cancer 2017 5:22

    Published on: 21 March 2017

  15. Research article

    Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy

    Insufficient persistence and effector function of chimeric antigen receptor (CAR)-redirected T cells have been challenging issues for adoptive T cell therapy. Generating potent CAR T cells is of increasing imp...

    Ryan Urak, Miriam Walter, Laura Lim, ChingLam W. Wong, Lihua E. Budde, Sandra Thomas, Stephen J. Forman and Xiuli Wang

    Journal for ImmunoTherapy of Cancer 2017 5:26

    Published on: 21 March 2017

  16. Short report

    Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade

    Monoclonal antibodies that block immune regulatory proteins such as programmed death-1 (PD-1) have demonstrated remarkable efficacy in controlling the growth of multiple tumor types. Unresectable or metastatic...

    Evan J. Lipson, Mohammed T. Lilo, Aleksandra Ogurtsova, Jessica Esandrio, Haiying Xu, Patricia Brothers, Megan Schollenberger, William H. Sharfman and Janis M. Taube

    Journal for ImmunoTherapy of Cancer 2017 5:23

    Published on: 21 March 2017

  17. Research article

    CCR7+ selected gene-modified T cells maintain a central memory phenotype and display enhanced persistence in peripheral blood in vivo

    Adoptive T cell immunotherapy (ATCT) for cancer entails infusing patients with T cells that recognise and destroy tumour cells. Efficient engraftment of T cells and persistence in the circulation correlate wit...

    Gray Kueberuwa, Hannah Gornall, Erik Marcelo Alcantar-Orozco, Deborah Bouvier, Zainul Abedin Kapacee, Robert Edward Hawkins and David Edward Gilham

    Journal for ImmunoTherapy of Cancer 2017 5:14

    Published on: 21 February 2017

  18. Research article

    Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen

    We previously demonstrated that tumor irradiation potentiates cancer vaccines using genetic modification of tumor cells in murine tumor models. To investigate whether tumor irradiation augments the immune resp...

    Gilda G. Hillman, Lyndsey A. Reich, Shoshana E. Rothstein, Lisa M. Abernathy, Matthew D. Fountain, Kali Hankerd, Christopher K. Yunker, Joseph T. Rakowski, Eric Quemeneur and Philippe Slos

    Journal for ImmunoTherapy of Cancer 2017 5:4

    Published on: 17 January 2017

  19. Case report

    Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma

    Renal medullary carcinoma (RMC) is a rare kidney tumor that occurs in adolescent and young adults, typically in association with sickle cell trait. RMC exhibits rapid disease progression, frequent metastases a...

    Kathryn E. Beckermann, Pradeep C. Jolly, Ju Y. Kim, Jennifer Bordeaux, Igor Puzanov, W. Kimryn Rathmell and Douglas B. Johnson

    Journal for ImmunoTherapy of Cancer 2017 5:1

    Published on: 17 January 2017

Previous Page Page 1 of 4 Next Page
JITC logo

Advertisement